Skip to content

    TG THERAPEUTICS (TGTX) stock price & financials

    View TGTX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+88.8% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $83.88M
    $108.19M
    $120.86M
    $141.15M
    $161.71M
    +92.8%
    $192.57M
    +78.0%
    $204.92M
    +69.6%
    $240.34M
    +70.3%
    Strengthening
    Operating Profit
    $12.43M
    $29.95M
    $8.62M
    $34.84M
    $29.36M
    +136.2%
    $50.49M
    +68.6%
    $34.80M
    +303.6%
    $21.67M
    -37.8%
    Strengthening
    Net Profit
    $3.88M
    $23.33M
    $5.06M
    $28.19M
    $390.89M
    +9974.6%
    $23.04M
    -1.3%
    $19.78M
    +290.8%
    $7.78M
    -72.4%
    Strengthening
    EPS
    $0.03
    $0.03
    $0.19
    $2.69
    +8866.7%
    $0.14
    +366.7%
    $0.05
    -73.7%
    Strengthening
    Other Income
    -$8.17M
    -$4.50M
    -$3.15M
    -$3.92M
    -$3.46M
    +57.7%
    -$5.40M
    -20.1%
    -$14.43M
    -357.6%
    -$11.44M
    -191.6%
    Weakening
    Interest
    $10.83M
    $6.93M
    $6.76M
    $6.72M
    $6.72M
    -38.0%
    $6.53M
    -5.7%
    $7.67M
    +13.5%
    $16.57M
    +146.8%
    Strengthening
    Depreciation
    Profit before Tax
    $4.27M
    $25.45M
    $5.47M
    $30.92M
    $25.91M
    +507.1%
    $45.09M
    +77.2%
    $20.36M
    +272.4%
    $10.23M
    -66.9%
    Strengthening
    MarginsOPM
    14.8%
    27.7%
    7.1%
    24.7%
    18.2%
    +22.5%
    26.2%
    -5.3%
    17.0%
    +138.1%
    9.0%
    -63.5%
    Strengthening
    Tax
    9.1%
    8.3%
    7.5%
    8.8%
    -1408.7%
    -15597.5%
    48.9%
    +486.5%
    2.9%
    -61.4%
    24.0%
    +171.2%
    Strengthening
    ReturnsROIC
    -0.4%
    -2.2%
    -0.5%
    -2.7%
    -37.1%
    -9974.6%
    -2.2%
    +1.3%
    -1.9%
    -290.8%
    -0.7%
    +72.4%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$41.96M$112.64M$553.44M$298.89M$102.30M$92.93M$179.89M$79.15M$482.57M
    Short-Term Investments
    Total Current Assets$79.03M$149.15M$611.74M$330.96M$168.27M$317.94M$566.36M$630.76M$1.15B
    Net PP&E$251.0K$9.68M$9.79M$9.23M$9.20M$8.14M$7.15M$6.28M$7.08M
    Goodwill$799.0K$799.0K$799.0K$799.0K$799.0K$799.0K
    Intangibles
    Total Assets$83.62M$163.01M$625.64M$379.63M$193.57M$329.59M$577.69M$1.06B$1.64B
    LiabilitiesTotal Current Liabilities$38.85M$84.45M$87.55M$65.38M$53.20M$53.72M$90.68M$153.76M$268.49M
    Short-Term Debt$0$22.18M$975.0K$0
    Long-Term Debt$0$28.97M$7.72M$66.79M$71.14M$100.12M$244.43M$245.65M$745.39M
    Long-Term Leases$0$10.22M$10.41M$9.85M$10.34M$9.23M$8.13M$7.02M$7.14M
    Total Liabilities$59.58M$124.40M$106.29M$142.48M$134.99M$169.09M$355.33M$415.23M$1.04B
    EquityCommon Stock & APIC$84.0K$109.0K$141.0K$143.0K$146.0K$151.0K$156.0K$159.0K$160.0K
    Retained Earnings-$528.35M-$701.22M-$980.60M-$1.33B-$1.53B-$1.55B-$1.53B-$1.08B-$1.05B
    Total Equity$24.04M$38.62M$519.35M$237.15M$58.59M$160.50M$222.36M$648.02M$604.08M
    HighlightsNet Cash / (Debt)$83.67M$523.54M$231.12M$31.17M

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$128.93M-$132.81M-$214.51M-$295.63M-$176.17M-$31.41M-$40.52M-$24.77M$17.88M
    Cash from Investing$1.18M-$718.0K-$24.51M-$332.0K-$20.01M-$50.65M-$1.04M$13.80M$21.89M
    Cash from Financing$113.64M$204.21M$679.83M$41.42M-$391.0K$72.70M$128.53M-$89.73M$313.73M
    SummaryCapital Expenditure-$90.0K-$131.0K-$357.0K-$401.0K-$14.0K$0-$45.0K-$214.0K-$491.0K
    Free Cash Flow-$129.01M-$132.94M-$214.86M-$296.04M-$176.18M-$31.41M-$40.56M-$24.99M$17.39M
    FCF Margin-84878.3%-87458.6%-141357.9%-4425.7%-6326.2%-13.4%-12.3%-4.1%2.2%

    Ratios